Guided Therapeutics (GTHP) EBITDA Margin (2010 - 2025)
Guided Therapeutics (GTHP) posted EBITDA Margin of 120.34% for Q4 2025, up 85.11% sequentially from 808.33% in Q3 2025, and up 5327966.0% YoY from N/an in Q4 2024.
Guided Therapeutics (GTHP) EBITDA Margin (2010 - 2025) Analysis & Trends
Guided Therapeutics has reported EBITDA Margin for 16 years, with the latest figure at 120.34% in Q4 2025.
- Quarterly EBITDA Margin rose 5327966.0% year-over-year to 120.34% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 309.26% (up 2981931.0% YoY) and the FY2025 annual result came in at 309.26%, up 2980503.0% from the prior year.
- EBITDA Margin climbed to 120.34% in Q4 2025 per GTHP's latest filing, from 808.33% in the prior quarter.
- Over five years, EBITDA Margin peaked at 120.34% in Q4 2025 and troughed at 53400.0% in Q4 2024.
- A 5-year average of 11790.73% and a median of 3626.14% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin slumped 5188438 bps in 2024, then jumped 5327966 bps in 2025.
- Over 5 years, EBITDA Margin stood at 725.0% in 2021, then sank by 5528 bps to 40800.0% in 2022, then surged by 96 bps to 1515.62% in 2023, then slumped by 3423 bps to 53400.0% in 2024, then soared by 100 bps to 120.34% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 120.34%, 808.33%, and 652.14% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.61 Bn | 194.01 Bn | 7.27 Bn | 13.44% |
| 2 | Stryker | 127.81 Bn | 124.34 Bn | 4.50 Bn | 25.18% |
| 3 | Medtronic | 119.04 Bn | 109.82 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 73.68 Bn | 73.14 Bn | 3.85 Bn | 21.65% |
| 5 | Edwards Lifesciences | 51.96 Bn | 47.71 Bn | 1.35 Bn | 29.48% |
| 6 | Dexcom | 34.36 Bn | 32.41 Bn | 830.00 Mn | 24.33% |
| 7 | GE HealthCare Technologies | 33.83 Bn | 31.72 Bn | 2.18 Bn | 13.96% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 10.30% |
| 9 | Steris | 23.06 Bn | 22.58 Bn | 684.20 Mn | 19.15% |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -120.34% |
| Sep 30, 2025 | -808.33% |
| Jun 30, 2025 | -652.14% |
| Dec 31, 2024 | -53,400.00% |
| Mar 31, 2024 | -5,983.33% |
| Dec 31, 2023 | -1,515.63% |
| Jun 30, 2023 | -3,420.45% |
| Mar 31, 2023 | -3,831.82% |
| Sep 30, 2022 | -40,800.00% |
| Jun 30, 2022 | -14,340.00% |
| Mar 31, 2022 | -8,860.00% |
| Dec 31, 2021 | -725.00% |
| Sep 30, 2021 | -2,563.16% |
| Jun 30, 2021 | -28,050.00% |
| Dec 31, 2020 | -1,152.00% |
| Sep 30, 2020 | -198.70% |
| Dec 31, 2019 | -1,031.25% |
| Sep 30, 2019 | -18,800.00% |
| Jun 30, 2019 | -32,700.00% |
| Mar 31, 2019 | -1,427.78% |